- Home
- LXEO vs VATE Comparison
LXEO vs VATE Comparison
Compare LXEO & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- VATE
- Stock Information
- Founded
- LXEO 2017
- VATE 1994
- Country
- LXEO United States
- VATE United States
- Employees
- LXEO N/A
- VATE N/A
- Industry
- LXEO
- VATE Metal Fabrications
- Sector
- LXEO
- VATE Industrials
- Exchange
- LXEO Nasdaq
- VATE Nasdaq
- Market Cap
- LXEO 93.9M
- VATE 98.2M
- IPO Year
- LXEO 2023
- VATE 1996
- Fundamental
- Price
- LXEO $2.78
- VATE $5.30
- Analyst Decision
- LXEO Strong Buy
- VATE
- Analyst Count
- LXEO 6
- VATE 0
- Target Price
- LXEO $18.50
- VATE N/A
- AVG Volume (30 Days)
- LXEO 984.8K
- VATE 45.1K
- Earning Date
- LXEO 05-12-2025
- VATE 05-06-2025
- Dividend Yield
- LXEO N/A
- VATE N/A
- EPS Growth
- LXEO N/A
- VATE N/A
- EPS
- LXEO N/A
- VATE N/A
- Revenue
- LXEO N/A
- VATE $1,066,100,000.00
- Revenue This Year
- LXEO N/A
- VATE N/A
- Revenue Next Year
- LXEO N/A
- VATE N/A
- P/E Ratio
- LXEO N/A
- VATE N/A
- Revenue Growth
- LXEO N/A
- VATE N/A
- 52 Week Low
- LXEO $1.45
- VATE $3.25
- 52 Week High
- LXEO $19.50
- VATE $13.79
- Technical
- Relative Strength Index (RSI)
- LXEO 45.92
- VATE 40.07
- Support Level
- LXEO $2.51
- VATE $5.63
- Resistance Level
- LXEO $2.91
- VATE $8.28
- Average True Range (ATR)
- LXEO 0.38
- VATE 0.69
- MACD
- LXEO -0.04
- VATE -0.05
- Stochastic Oscillator
- LXEO 33.62
- VATE 0.00
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.